Testing tumor samples after BMS cell therapy and a second cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial offers testing of tumor samples for people who developed a new, different cancer after receiving a Bristol-Myers Squibb gene-modified cell therapy. The goal is to understand the genetics of that new cancer and see if it relates to the prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were treated with a Bristol-Myers Squibb (BMS) gene-modified cell therapy (a type of personalized cancer treatment).
- After that treatment, you were diagnosed with a new, different cancer (a second primary malignancy).
- You are not currently in another clinical trial that is collecting your samples and information for that trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who developed a new T-cell cancer after receiving the CAR-T therapy tisagenlecleucel (Kymriah). Researchers want to understand these rare cancers by testing stored tumor samples. You may be eligible if you had tisagenlecleucel and were later diagnosed with a T-cell malignancy.
This Phase 2 study uses a team review of your tumor’s gene test results to help match you with treatments you may benefit from. It’s designed for people whose tumor has specific gene changes that suggest sensitivity to available medicines or may involve inherited (germline) risk.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests a new type of cell therapy (BGT007H cells) for people with advanced gastrointestinal cancers that have not responded to at least two standard treatments. The therapy uses your own immune cells that are modified to target and attack the cancer.
This trial takes a sample of your tumor during a standard procedure to grow it in a lab and test different drugs. The goal is to find which drugs might work best for people with your specific tumor DNA change.
This trial looks at your tumor (and blood) to find helpful targets so doctors can match you to an experimental targeted therapy, if one fits. It may help by using detailed “tumor profiling” to choose treatments more precisely for your cancer.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.